Prostate Cancer Diagnostics Market To Reach $13.16 Billion By 2030

Prostate Cancer Diagnostics Market Growth & Trends

The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030,according to a new report by Grand View Research, Inc. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market.

A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled ‘Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress’ (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.

Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.

Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.

 Request a free sample copy or view report summary: Prostate Cancer Diagnostics Market Report

Prostate Cancer Diagnostics Market Report Highlights

• Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion

• Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician

• The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis

Prostate Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global prostate cancer diagnostics market report based on test type, type, end-use, and region

Prostate Cancer Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Preliminary Tests

  • PSA Tests

  • Free PSA Test

  • Total PSA Test

  • Other Preliminary Tests

• Confirmatory Tests

  • Pca3 Test

  • Trans-Rectal Ultrasound

  • Biopsy Test

Prostate Cancer Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Adenocarcinoma

• Interstitial Cell Carcinoma

• Other

Prostate Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Outpatient Facilities

• Home Care

• Research & Manufacturing

Prostate Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Prostate Cancer Diagnostics Market

• MDx Health

• Myriad Genetics, Inc.

• Abbott Laboratories

• F. Hoffman-La Roche AG

• Bayer AG

• Siemens Healthcare GmbH

• OPKO Health, Inc.

• Genomic Health.

• Pfizer Inc.